MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults.
Xianhui Qin, Jianping Li, Yimin Cui...
https://pubmed.ncbi.nlm.nih.gov/22230384/Actively Recruiting
Led by Shenzhen Ausa Pharmed Co.,Ltd · Updated on 2025-02-26
24000
Participants Needed
20
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of different amlodipine-based treatments on the risk of first ischemic stroke in Chinese adults aged 45 to 74 years with hypertension and the MTHFR 677 TT genotype. This large, multi-center, randomized, double-blind, triple-dummy controlled trial aims to compare amlodipine alone, amlodipine combined with folic acid, and amlodipine combined with folic acid plus 5-methyltetrahydrofolate over a 5-year period. The study focuses on preventing ischemic stroke as the primary outcome. Participants first undergo a screening period to confirm eligibility through interviews, clinical evaluations, and lab tests. Those who qualify enter a 2 to 4 week run-in phase with daily amlodipine to check treatment tolerance and compliance. Eligible participants are then randomly assigned to one of three daily oral treatment groups amlodipine alone, amlodipine folic acid, or amlodipine folic acid plus 5-MTHF. Additional antihypertensive medications may be added as needed to control blood pressure. Participants are followed every 3 months for drug distribution and monitoring. Throughout the study, participants will have regular clinical visits, interviews, and biological sample collections to monitor health and treatment effects. Researchers will track the incidence of first ischemic stroke and other cardiovascular and kidney outcomes over five years. Safety and treatment adherence are carefully observed, with two planned interim analyses during the trial. Total participation spans from initial screening through five years of treatment and follow-up.
CONDITIONS
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
M
Minqing Tian, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shenzhen Ausa Pharmed Co.,Ltd
Lead Sponsor
Peking University First Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for informed consent, interview, clinical evaluation, and sample collection
Duration - 2 to 4 weeks
Participants take amlodipine once daily to assess compliance and tolerance before randomization.
1 visit to start treatment and monitoring during this period
Duration - Up to 5 years
Participants receive randomized treatment with different amlodipine and folic acid formulations to prevent first ischemic stroke.
Quarterly visits every 3 months for follow-up and medication distribution
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Xianhui Qin, Jianping Li, Yimin Cui...
https://pubmed.ncbi.nlm.nih.gov/22230384/Xianhui Qin, Youbao Li, Ningling Sun...
https://pubmed.ncbi.nlm.nih.gov/27834686/Xianhui Qin, Jianping Li, Yimin Cui...
https://pubmed.ncbi.nlm.nih.gov/21869730/Xiao Huang, Youbao Li, Ping Li...
https://pubmed.ncbi.nlm.nih.gov/29030456/B Wilcken, F Bamforth, Z Li...
https://pubmed.ncbi.nlm.nih.gov/12920077/Qing Dong, Genfu Tang, Mingli He...
https://pubmed.ncbi.nlm.nih.gov/22897803/Xiaowei Xu, Jiejie Li, Wenli Sheng...
https://pubmed.ncbi.nlm.nih.gov/18511872/Homocysteine Lowering Trialists’ Collaboration
https://pubmed.ncbi.nlm.nih.gov/9569395/Xianhui Qin, Jianping Li, Yan Zhang...
https://pubmed.ncbi.nlm.nih.gov/22880024/Homocysteine Lowering Trialists' Collaboration
https://pubmed.ncbi.nlm.nih.gov/16210710/Shenzhen Ausa Pharmed Co.,Ltd
Lead Sponsor
Peking University First Hospital
Collaborating Sponsor